Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand

Antimicrob Agents Chemother. 2011 Nov;55(11):5388-91. doi: 10.1128/AAC.05517-11. Epub 2011 Aug 29.

Abstract

A 21-year survey conducted in northeast Thailand of antimicrobial resistance to parenteral antimicrobial drugs used to treat melioidosis identified 24/4,021 (0.6%) patients with one or more isolates resistant to ceftazidime (n = 8), amoxicillin-clavulanic acid (n = 4), or both drugs (n = 12). Two cases were identified at admission, and the remainder were detected a median of 15 days after starting antimicrobial therapy. Resistance to carbapenem drugs was not detected. These findings support the current prescribing recommendations for melioidosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Burkholderia pseudomallei / drug effects*
  • Burkholderia pseudomallei / pathogenicity*
  • Ceftazidime / therapeutic use
  • Drug Resistance, Bacterial
  • Humans
  • Imipenem / therapeutic use
  • Melioidosis / drug therapy
  • Meropenem
  • Thailand
  • Thienamycins / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • Imipenem
  • Amoxicillin-Potassium Clavulanate Combination
  • Ceftazidime
  • Meropenem